Image source: Getty Images.
Investing in beaten-up biotech stocks is usually a difficult proposition. Drug companies typically plummet after bad news — a failed clinical trial or a Food and Drug Administration rejection, for instance — making it hard for them to come back, especially since raising additional capital at the beaten-down price can cause substantial dilution of shareholders.